New share issue in Biovitrum AB (publ)

In accordance with Biovitrum stock option program 2006:5 TO6
2006/2009, 180,756 new shares have been issued at the price SEK 59.00
per share, resulting in Biovitrum being provided funds of a total of
SEK 10,664,604.00. The number of remaining stock options in the stock
option program 2006:5 TO6 2006/2008 is 417,190.

After the share issue the outstanding number of shares in Biovitrum
is 50,282,538.

For more information please contact:
Biovitrum
Göran Arvidson, CFO
Phone: +46 8 697 23 68

Erik Kinnman, VP Investor Relations
Phone: +46 8 697 21 50
erik.kinnman@biovitrum.com


About Biovitrum
Biovitrum is  an international  pharmaceutical company  that  markets
specialist pharmaceuticals  in several  regions globally.  Using  its
expertise and  experience Biovitrum  takes scientific  innovation  to
patients with significant unmet medical need. Research expertise  and
capabilities  are   focused   on  development   and   production   of
biotechnology  therapeutics   within   our   prioritized   areas   of
hemophilia, inflammation/autoimmune diseases, cancer supportive  care
and malabsorption. The company has revenues of approximately SEK  1.2
billion and around 400 employees. The company head office is  located
in Sweden and it is listed on the Stockholm OMX Nordic Exchange.  For
more information please visit  www.biovitrum.com.



Biovitrum AB (publ) may be required to disclose the information
provided herein pursuant to the Swedish Securities Markets Act. The
information was provided for public release on May 29, 2009 at 16:00
p.m. CET.